Agilon Health, Inc. $AGL Shares Purchased by CenterBook Partners LP

CenterBook Partners LP raised its position in Agilon Health, Inc. (NYSE:AGL) by 492.4% during the 3rd quarter, Holdings Channel reports. The firm owned 11,428,027 shares of the company’s stock after acquiring an additional 9,499,012 shares during the quarter. CenterBook Partners LP’s holdings in Agilon Health were worth $11,771,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Agilon Health in the 2nd quarter worth about $31,000. Wealthcare Advisory Partners LLC acquired a new position in Agilon Health during the third quarter worth about $26,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Agilon Health in the second quarter valued at about $68,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Agilon Health in the third quarter valued at about $37,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Agilon Health by 214.0% in the second quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock valued at $85,000 after purchasing an additional 25,270 shares during the last quarter.

Key Agilon Health News

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Management will participate in the Cowen Healthcare Conference (March 2) and Jefferies summit, providing a near-term opportunity for management to update investors and answer questions about operations and outlook. agilon health to Participate in Upcoming Conferences
• Neutral Sentiment: Agilon is expected to announce quarterly earnings this week — the report and any guidance/comments will be a key catalyst that could move the stock in either direction. Agilon Health (AGL) Expected to Announce Quarterly Earnings on Wednesday
• Negative Sentiment: Multiple law firms and litigation shops have announced class actions or are soliciting Agilon investors (alleging securities fraud for purchases between Feb. 26, 2025 and Aug. 4, 2025), raising the prospect of shareholder litigation and related costs. Example notice from Bragar Eagel & Squire. Bragar Eagel & Squire, P.C. Reminds Agilon Health, Inc. Investors…
• Negative Sentiment: Pomerantz and several other firms (Robbins LLP, Rosen, Bernstein Liebhard, Portnoy, Faruqi, Schall, etc.) have filed or publicized litigation/investigation notices and are soliciting lead plaintiffs ahead of a March 2 lead-plaintiff deadline — sustained legal activity typically pressures small-cap healthcare names. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…
• Negative Sentiment: Law firms and plaintiffs’ notices from PR Newswire and others (e.g., Frank R. Cruz, DJS Law Group) indicate active investigations into alleged securities violations — the possibility of settlement, legal fees, or damages is an overhang. agilon health, inc. (AGL) Shareholders Who Lost Money Have Opportunity to Lead…

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Zacks Research upgraded Agilon Health from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 21st. Barclays dropped their price target on Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a research report on Thursday, November 6th. Wells Fargo & Company cut their price target on Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Finally, Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agilon Health presently has a consensus rating of “Hold” and a consensus price target of $2.71.

Agilon Health Stock Down 1.9%

AGL stock opened at $0.35 on Wednesday. The stock has a market capitalization of $146.90 million, a price-to-earnings ratio of -0.47 and a beta of 0.06. Agilon Health, Inc. has a 52-week low of $0.34 and a 52-week high of $6.08. The stock’s fifty day simple moving average is $0.75 and its 200-day simple moving average is $0.88.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.